Credit: yourgenome/Flickr
Treatment with the molecule Thymosin α1 may decrease inflammation and correct genetic defects causing cystic fibrosis
Cystic fibrosis (CF) is a chronic condition which afflicts around 70,000 people around the world. Current treatments can manage the disease to a large degree but lifespan remains curtailed at roughly 40 years of age – commonly due to complications such as infection and antibiotic resistance.“Right now there are multiple treatments for cystic fibrosis, and while these have improved life expectancy dramatically, there is still only a lifespan of about 40 years for patients. No one treatment can stand alone. We developed a single treatment that can potentially correct the genetic defect that causes cystic fibrosis and decrease the inflammation that happens as a result”
Rescuing CFTR by Thymosin α1(T α1) acting as a corrector of the misfolded protein (p.Phe508del-CFTR) and potentiator of normal chloride channel activity. EC, epithelial cells. CFTR, cystic fibrosis transmembrane regulator protein. WT, wild-type (normal epithelial cells). Credit: University of Perugia
Copyright © Gowing Life Limited, 2023 • All rights reserved • Registered in England & Wales No. 11774353 • Registered office: Ivy Business Centre, Crown Street, Manchester, M35 9BG.